Motor impairment in Wilson's disease 3: the clinical impact of pyramidal tract involvement
Harald Hefter(Heinrich Heine University Düsseldorf), R. Benecke(Children's Hospital of Philadelphia), Gabriele Arendt(University of California San Diego), H. Roick(Heinrich Heine University Düsseldorf), H.‐J. von Giesen(Heinrich Heine University Düsseldorf), Wolfgang Stremmel(University Hospital Heidelberg), Peter H. Weiss
Cited by 16
Related Papers
Survival and Causes of Death in Cirrhotic and in Noncirrhotic Patients with Primary Hemochromatosis
|New England Journal of Medicine|1985|1.1k
Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?
|Nature Medicine|1996|906
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
|The Journal of Experimental Medicine|1998|897
Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.
|Journal of Clinical Investigation|1997|771
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.
|The Journal of Experimental Medicine|1995|700